Perrigo Eyes $115 Bil. Worth Of Rx-To-OTC Switches On The Horizon
This article was originally published in The Tan Sheet
The private labeler sees about $115 billion worth of branded Rx products with potential to switch OTC, including statins and longer-shot switches for diabetes, hypertension and topical steroid drugs. Perrigo’s shorter-term pipeline includes equivalents of proton pump inhibitors Nexium, Protonix and Aciphex.